New Jersey’s reputation as the “Medicine Chest of the World” just got a significant boost. Frontage Laboratories, Inc., a global leader in drug development research, announced Friday a major expansion of its clinical capabilities, with its Secaucus facility serving as the primary anchor for its U.S. operations.
The expansion is designed to help pharmaceutical and biotech companies move faster—and more cost-effectively—from the lab to the pharmacy shelf.
At the heart of this growth is Frontage’s state-of-the-art 160-bed clinical unit located at 200 Meadowlands Parkway. The 36,000-square-foot facility isn’t just a place for testing; it’s a high-tech hub capable of handling the industry’s most complex research.
Key upgrades to the Secaucus site include:
-
Radiolabeled research (hAME): A dedicated unit staffed by radiation experts and an on-site nuclear pharmacy. This allows scientists to track exactly how a new drug moves through the human body.
-
Bioequivalence (BE) powerhouse: As a wave of major drug patents expires in 2026, the Secaucus unit is now a primary destination for high-volume studies that prove generic versions of drugs are just as effective as the originals.
-
Oncology expansion: Responding to urgent medical needs, Frontage is partnering with regional New Jersey hospitals to conduct early-phase cancer trials, bringing cutting-edge research directly to patient populations.
In the world of drug development, “handoffs” between different labs can lead to delays and errors. Frontage is solving this with a “One-Stop Shop” model. By integrating the Secaucus clinical work with its manufacturing sites in Pennsylvania and its bioanalytical labs in China, the company says it can streamline the entire process.
This model is specifically designed to align with the FDA’s 2024 guidance, ensuring that New Jersey-based research meets the highest global regulatory standards.
“Our strategic growth enhances our ability to support partners with accelerated, high-quality solutions,” the company said in its announcement. “Vineland and Secaucus play critical roles in our growth today and well into the future.”
The expansion cements Secaucus as a vital link in the global drug supply chain. With its proximity to major medical centers and international airports, the facility allows for Multi-Regional Clinical Trials (MRCT)—meaning a drug can be tested simultaneously in New Jersey and overseas to speed up global approval.
For the local economy, this means a continued influx of high-value jobs for scientists, licensed radiation experts, and clinical coordinators right here in the Garden State.
